Anavex Life Sciences (AVXL) Liabilities and Shareholders Equity (2011 - 2026)
Anavex Life Sciences' Liabilities and Shareholders Equity came in at $120.14 million for fiscal Q3 2026 (quarter ended Jun 30, 2026), up 17.3% from $102.43 million a year earlier but down 6.7% from the prior quarter.
Powered by 
Analysis
Anavex Life Sciences (AVXL) Liabilities and Shareholders Equity (2011 - 2026) Analysis & Trends
At the end of FY2025 (ended Sep 30, 2025), Anavex Life Sciences' Liabilities and Shareholders Equity was $103.82 million, down 23.4% from FY2024.
- Liabilities and Shareholders Equity carries a five-year compound annual growth rate of 24.6% (FY2020 to FY2025).
- Going back by fiscal year, Liabilities and Shareholders Equity was $135.57 million in FY2024 (-12.2%), $154.39 million in FY2023 (+1.1%), $152.71 million in FY2022 (-5.5%) and $161.62 million in FY2021 (+367.9%).
- The five-year range for quarterly Liabilities and Shareholders Equity is $102.43 million (fiscal Q3 2025) to $161.62 million (fiscal Q4 2021).
- Year-over-year, Liabilities and Shareholders Equity has increased for three consecutive quarters, with an average decline of 8.0% over the last eight quarters.
- The fastest year-over-year change in Liabilities and Shareholders Equity over five years came in fiscal Q4 2021 (growth of 367.9%), and the weakest in fiscal Q3 2025 (a decline of 27.6%).
- Business Quant data shows AVXL's Liabilities and Shareholders Equity at $128.77 million (Q2 2026), $132.99 million (Q1 2026) and $103.82 million (Q4 2025) in the three fiscal quarters before Q3 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 638.12 Bn | 556.64 Bn | 17.26 Bn | 201.06 Bn |
| 2 | AbbVie | 462.60 Bn | 435.75 Bn | 12.70 Bn | 135.12 Bn |
| 3 | Merck | 358.70 Bn | 313.13 Bn | 12.21 Bn | 129.80 Bn |
| 4 | Novartis Ag | 272.16 Bn | 228.03 Bn | 11.24 Bn | 122.03 Bn |
| 5 | Astrazeneca | 250.36 Bn | 223.92 Bn | 12.86 Bn | 115.83 Bn |
| 6 | Amgen | 227.87 Bn | 183.27 Bn | 7.24 Bn | 95.64 Bn |
| 7 | Gilead Sciences | 184.97 Bn | 159.08 Bn | 6.22 Bn | 49.36 Bn |
| 8 | Pfizer | 162.61 Bn | 109.56 Bn | 10.94 Bn | 201.13 Bn |
| 9 | Vertex Pharmaceuticals | 132.45 Bn | 104.46 Bn | 2.84 Bn | 27.42 Bn |
| 10 | Anavex Life Sciences | 187.25 Mn | -292.83 Mn | - | 120.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 120.14 Mn |
| Mar 31, 2026 | 128.77 Mn |
| Dec 31, 2025 | 132.99 Mn |
| Sep 30, 2025 | 103.82 Mn |
| Jun 30, 2025 | 102.43 Mn |
| Mar 31, 2025 | 117.14 Mn |
| Dec 31, 2024 | 124.04 Mn |
| Sep 30, 2024 | 135.57 Mn |
| Jun 30, 2024 | 141.54 Mn |
| Mar 31, 2024 | 144.52 Mn |
| Dec 31, 2023 | 148.07 Mn |
| Sep 30, 2023 | 154.39 Mn |
| Jun 30, 2023 | 157.81 Mn |
| Mar 31, 2023 | 159.19 Mn |
| Dec 31, 2022 | 148.37 Mn |
| Sep 30, 2022 | 152.71 Mn |
| Jun 30, 2022 | 160.22 Mn |
| Mar 31, 2022 | 160.28 Mn |
| Dec 31, 2021 | 156.90 Mn |
| Sep 30, 2021 | 161.62 Mn |
API Access
Anavex Life Sciences Liabilities and Shareholders Equity API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=AVXL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "liabilities-and-shareholders-equity", "ticker": "AVXL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=liabilities-and-shareholders-equity&ticker=AVXL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();